Delcath Systems, Inc. (DCTH)
DCTH Stock Price Chart
Explore Delcath Systems, Inc. interactive price chart. Choose custom timeframes to analyze DCTH price movements and trends.
DCTH Company Profile
Discover essential business fundamentals and corporate details for Delcath Systems, Inc. (DCTH) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Medical - Devices
IPO Date
3 May 2018
Employees
96.00
Website
https://www.delcath.comCEO
Gerard J. Michel
Description
Delcath Systems, Inc. is an interventional oncology firm operating in the United States and Europe, dedicated to developing treatments for both primary and secondary liver cancers. Its leading investigational product is the HEPZATO KIT, a unique hepatic delivery system for melphalan that targets high-dose chemotherapy specifically to the liver. This innovative approach aims to substantially reduce systemic drug exposure and mitigate associated side effects. HEPZATO's clinical evaluation is advancing through the FOCUS trial, which is designed to assess the objective response rate in individuals with metastatic uveal melanoma whose disease is primarily concentrated in the liver. Furthermore, the company offers a separate version of HEPZATO as a medical device in Europe, marketed under the CHEMOSAT Hepatic Delivery System brand (or simply CHEMOSAT). This system empowers European medical centers to manage a diverse array of liver cancer conditions. Delcath Systems, Inc. was established in 1988, with its corporate headquarters situated in New York, New York.
DCTH Financial Timeline
Browse a chronological timeline of Delcath Systems, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 5 Aug 2026
EPS estimate is -$0.09, while revenue estimate is $26.26m.
Earnings released on 7 May 2026
EPS came in at -$0.03 surpassing the estimated -$0.09 by +68.09%, while revenue for the quarter reached $25.00m , beating expectations by +6.34%.
Earnings released on 26 Feb 2026
EPS came in at -$0.05 surpassing the estimated -$0.06 by +20.62%, while revenue for the quarter reached $20.73m , beating expectations by +0.74%.
Earnings released on 4 Nov 2025
EPS came in at $0.02 matching the estimated $0.02, while revenue for the quarter reached $20.56m , beating expectations by +1.03%.
Earnings released on 6 Aug 2025
EPS came in at $0.07 surpassing the estimated $0.03 by +169.23%, while revenue for the quarter reached $24.16m , beating expectations by +4.92%.
Earnings released on 8 May 2025
EPS came in at $0.03 falling short of the estimated $0.10 by -70.00%, while revenue for the quarter reached $19.78m , beating expectations by +6.11%.
Earnings released on 6 Mar 2025
EPS came in at $0.05 surpassing the estimated -$0.10 by +150.00%, while revenue for the quarter reached $15.10m , missing expectations by -9.43%.
Earnings released on 8 Nov 2024
EPS came in at -$0.03 surpassing the estimated -$0.13 by +76.92%, while revenue for the quarter reached $9.56m , missing expectations by -23.03%.
Earnings released on 5 Aug 2024
EPS came in at -$0.48 falling short of the estimated -$0.34 by -41.18%, while revenue for the quarter reached $7.77m , missing expectations by -19.02%.
Earnings released on 14 May 2024
EPS came in at -$0.43 matching the estimated -$0.43, while revenue for the quarter reached $3.14m , beating expectations by +43.33%.
Earnings released on 26 Mar 2024
EPS came in at -$0.48 surpassing the estimated -$0.67 by +28.36%, while revenue for the quarter reached $539.00k , missing expectations by -0.19%.
Earnings released on 13 Nov 2023
EPS came in at -$0.61 falling short of the estimated -$0.51 by -19.61%, while revenue for the quarter reached $434.00k , missing expectations by -19.63%.
Earnings released on 9 Aug 2023
EPS came in at -$0.58 surpassing the estimated -$0.67 by +13.43%, while revenue for the quarter reached $495.00k , missing expectations by -33.11%.
Earnings released on 22 May 2023
EPS came in at -$0.77 falling short of the estimated -$0.62 by -25.01%, while revenue for the quarter reached $597.00k , missing expectations by -16.88%.
Earnings released on 27 Mar 2023
EPS came in at -$0.86 falling short of the estimated -$0.68 by -26.47%, while revenue for the quarter reached $639.00k , missing expectations by -21.11%.
Earnings released on 8 Nov 2022
EPS came in at -$0.92 surpassing the estimated -$1.05 by +12.38%, while revenue for the quarter reached $906.00k , beating expectations by +13.08%.
Earnings released on 8 Aug 2022
EPS came in at -$1.18 falling short of the estimated -$0.88 by -34.09%, while revenue for the quarter reached $797.00k , beating expectations by +92.35%.
Earnings released on 10 May 2022
EPS came in at -$1.00 falling short of the estimated -$0.84 by -19.05%, while revenue for the quarter reached $378.00k , missing expectations by -43.84%.
Earnings released on 25 Mar 2022
EPS came in at -$0.69 surpassing the estimated -$0.93 by +25.81%, while revenue for the quarter reached $2.11m , beating expectations by +306.95%.
Earnings released on 9 Nov 2021
EPS came in at -$0.94 falling short of the estimated -$0.91 by -3.30%, while revenue for the quarter reached $522.00k , beating expectations by +6.53%.
Earnings released on 10 Aug 2021
EPS came in at -$0.96 surpassing the estimated -$0.98 by +2.04%, while revenue for the quarter reached $536.00k , meeting expectations.
DCTH Stock Performance
Access detailed DCTH performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
